Julia‐Tatjana Maul

ORCID: 0000-0002-9914-1545
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Psoriasis: Treatment and Pathogenesis
  • Dermatology and Skin Diseases
  • Health Systems, Economic Evaluations, Quality of Life
  • Cutaneous Melanoma Detection and Management
  • Autoimmune Bullous Skin Diseases
  • Pharmaceutical studies and practices
  • Asthma and respiratory diseases
  • Allergic Rhinitis and Sensitization
  • Contact Dermatitis and Allergies
  • Urticaria and Related Conditions
  • Hidradenitis Suppurativa and Treatments
  • Spondyloarthritis Studies and Treatments
  • Nail Diseases and Treatments
  • Drug-Induced Adverse Reactions
  • Complementary and Alternative Medicine Studies
  • Cutaneous lymphoproliferative disorders research
  • Mast cells and histamine
  • Colorectal and Anal Carcinomas
  • Fibromyalgia and Chronic Fatigue Syndrome Research
  • AI in cancer detection
  • Microscopic Colitis
  • Biosimilars and Bioanalytical Methods
  • Skin Protection and Aging
  • Autoimmune and Inflammatory Disorders
  • Infection Control and Ventilation

University of Zurich
2017-2025

University Hospital of Zurich
2016-2025

University of Freiburg
2024

University Medical Center Freiburg
2024

Novartis (Switzerland)
2023

Drexel University
2023

University of South Florida
2023

Helsinki University Hospital
2023

Technical University of Munich
2023

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2023

Abstract This evidence‐ and consensus‐based guideline on the treatment of psoriasis vulgaris was developed following EuroGuiDerm Guideline Consensus Statement Development Manual. The first part includes general information scope purpose, health questions covered, target users strength/limitations guideline. Suggestions for disease severity grading goals are provided. It presents recommendations as well detailed management monitoring individual drugs. options discussed in this follows:...

10.1111/jdv.16915 article EN cc-by-nc Journal of the European Academy of Dermatology and Venereology 2020-11-01

Abstract This evidence‐ and consensus‐based guideline on the treatment of psoriasis vulgaris was developed following EuroGuiDerm Guideline Consensus Statement Development Manual. The second part provides guidance for specific clinical comorbid situations such as treating patient with concomitant psoriatic arthritis, inflammatory bowel disease, a history malignancies or depression suicidal ideation. It further holds recommendations diabetes, viral hepatitis, disease affecting heart kidneys...

10.1111/jdv.16926 article EN cc-by-nc Journal of the European Academy of Dermatology and Venereology 2021-02-01

Pyoderma gangrenosum (PG) is a rare, neutrophilic, ulcerative skin disease that difficult to treat, especially when unresponsive steroids.To determine whether canakinumab an effective and safe treatment in PG.Five adult patients with clinically histologically confirmed steroid-refractory PG were enrolled this prospective open-label study. They received 150 mg subcutaneously at week 0 optional 2 case of inadequate response [Physician's Global Assessment (PGA) ≥ 2], 150-300 8 depending on PGA....

10.1111/bjd.14037 article EN cc-by-nc-nd British Journal of Dermatology 2015-10-16

Though patient needs are key drivers of treatment decisions, they rarely systematically investigated in routine care.This study aimed at analysing and expectations from the perspective German Swiss psoriasis registries PsoBest Dermatology Network Targeted Therapies (SDNTT) with respect to choice, age gender.The observe patients recruited first-time use systemic drugs. Within 10 years, clinical [Psoriasis Area Severity Index (PASI), Body Surface (BSA)] patient-reported outcomes documented,...

10.1111/jdv.15324 article EN Journal of the European Academy of Dermatology and Venereology 2018-11-02

Dry skin is a frequent and multifaceted condition which can be associated with irritation, itch, patient discomfort manifest disease. In spite of being frequent, little known about the epidemiology dry in population.To determine prevalence German adult population.Data 48 630 employed persons were assessed on cross-sectional level whole-body examinations by experienced dermatologists during company-based screenings conducted 343 companies. Next to current dermatologic findings, age, gender,...

10.1111/jdv.15157 article EN Journal of the European Academy of Dermatology and Venereology 2018-06-28

Abstract Background Artificial intelligence (AI) shows promising potential to enhance human decision‐making as synergistic augmented (AuI), but requires critical evaluation for skin cancer screening in a real‐world setting. Objectives To investigate the perspectives of patients and dermatologists after by human, artificial intelligence. Methods A prospective comparative cohort study conducted at University Hospital Basel included 205 (at high‐risk developing melanoma, with resected or...

10.1111/jdv.19905 article EN Journal of the European Academy of Dermatology and Venereology 2024-02-27

The exponential increase in algorithm-based mobile health (mHealth) applications (apps) for melanoma screening is a reaction to growing market. However, the performance of available apps remains be investigated. In this prospective study, we investigated diagnostic accuracy class 1 CE-certified smartphone app risk stratification and its patient dermatologist satisfaction. Pigmented skin lesions ≥ 3 mm any suspicious smaller were assessed by SkinVision® (SkinVision® B.V., Amsterdam,...

10.3390/cancers14153829 article EN Cancers 2022-08-07

Convolutional neural networks (CNNs) have outperformed dermatologists in classifying pigmented skin lesions under artificial conditions. We investigated, for the first time, performance of three-dimensional (3D) and two-dimensional (2D) CNNs early detection melanoma a real-world setting.In this prospective study, 1690 melanocytic 143 patients with high-risk criteria were evaluated by dermatologists, 2D-FotoFinder-ATBM 3D-Vectra WB360 total body photography (TBP). Excision was based on...

10.1016/j.ejca.2023.112954 article EN cc-by European Journal of Cancer 2023-06-24

Quality of life impairment in dermatology patients and severity psoriasis are quantified by the Dermatology Life Index (DLQI) Psoriasis Area Severity (PASI), respectively. The aim this study is to compare correlation between PASI DLQI from different geographical areas identify predictors high across regions. Correlations were evaluated using Spearman’s rank tests quantile regression. included 1,158 with psoriasis, a median (interquartile range) 6.0 (3.0–12.0) 8.0 (4.0–15.0), demonstrated...

10.2340/actadv.v104.20329 article EN cc-by-nc Acta Dermato Venereologica 2024-03-12

Abstract Background Generalized pustular psoriasis (GPP) is a rare, inflammatory skin disease characterized by widespread eruption of sterile pustules with or without systemic symptoms. Objectives This study aimed to describe the demographics patients GPP in Central and Eastern Europe (CEE), present clinical characteristics individual flares explore current treatment landscape. Methods Patient were collected at times last observation previous treatment. Characteristics patient's (most...

10.1111/jdv.19808 article EN cc-by-nc Journal of the European Academy of Dermatology and Venereology 2024-01-27

This nationwide cohort study included 452 patients (873 treatment series) and reported drug survival data on with hidradenitis suppurativa treated biologics such as adalimumab, infliximab, ustekinumab secukinumab. The median time for adalimumab was approximately 8 months, but bio-naïve had a significantly longer compared non-naïve patients.

10.1093/bjd/ljae042 article EN British Journal of Dermatology 2024-02-02

Epidermal growth factor receptor (EGFR) and MEK inhibitors (EGFRi/MEKi) are beneficial for the treatment of solid cancers but frequently associated with severe therapy-limiting acneiform skin toxicities. The underlying molecular mechanisms poorly understood. Using gene expression profiling we identified IL-36γ IL-8 as candidate drivers EGFRi/MEKi toxicity. We provide translational evidence that in concert commensal bacterium Cutibacterium acnes act synergistically to induce keratinocytes...

10.1172/jci128678 article EN cc-by Journal of Clinical Investigation 2019-12-05

BACKGROUND: Seborrhoeic dermatitis is a common but epidemiologically poorly researched chronic skin disease. OBJECTIVES: To characterize the prevalence and dermatological comorbidity of seborrhoeic in Germany. METHODS: In course voluntary company checks, full-body examinations were carried out more than 500 companies by experienced dermatologists documented electronically. RESULTS: In total, 161 269 participants included (men 55·5%, mean age 43·2 ± 10·9 years). Seborrhoeic was...

10.1111/bjd.17826 article EN British Journal of Dermatology 2019-02-26

Few systematic data on sex-related treatment responses exist for psoriasis. To evaluate sex differences with respect to systemic antipsoriatic treatment. Data from patients moderate-to-severe psoriasis in the PsoBest or Swiss Dermatology Network of Targeted Therapies (SDNTT) registries were analysed. Treatment response was defined as achieving a ≥ 75% reduction Psoriasis Area and Severity Index (PASI 75) PASI ≤ 3 at months 3, 6 12, supplemented by patient-reported outcomes [i.e. Life Quality...

10.1111/bjd.20387 article EN British Journal of Dermatology 2021-04-10

Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy mild psoriasis or else in combination with UV systemic moderate-to-severe disease. For choice suitable topical treatment, formulation matters and not just active substances. This expert opinion paper was developed via non-structured consensus process by Swiss dermatologists hospitals private practices to illustrate current options general practitioners...

10.1159/000512930 article EN cc-by Dermatology 2021-01-01

The real-world efficacy of biologics may be insufficiently assessed through common drug survival studies. objective was thus to examine the performance in treatment psoriasis using composite endpoint either discontinuation or off-label dose escalation. Using a prospective nationwide registry (DERMBIO, 2007-2019), we included patients with treated adalimumab, secukinumab, and/or ustekinumab, which have all been used as first-line therapy during inclusion period. primary escalation treatment,...

10.1016/j.jid.2023.04.009 article EN cc-by Journal of Investigative Dermatology 2023-04-28

Importance The COVID-19 pandemic resulted in delayed access to medical care. Restrictions health care specialists, staff shortages, and fear of SARS-CoV-2 infection led interruptions routine care, such as early melanoma detection; however, premature mortality economic burden associated with this postponement have not been studied yet. Objective To determine the costs suspended screenings during lockdowns by estimating total diagnoses for Europe. Design, Setting, Participants This multicenter...

10.1001/jamanetworkopen.2023.56479 article EN cc-by-nc-nd JAMA Network Open 2024-02-16

Pregnancy-associated changes in melanocytic nevi (MN), apart from size increase on the trunk, remain a topic of debate. We conducted first prospective study to investigate dermoscopic MN comparing pregnant with non-pregnant women all body parts using market-approved convolutional neural network (CNN). included 25 and Basel, Switzerland, who underwent standard skin cancer screenings whose > 2 mm were digitally recorded analysed by CNN. Pregnant examined three times: third trimester 8-12 weeks...

10.2340/actadv.v105.41025 article EN cc-by-nc Acta Dermato Venereologica 2025-01-03

ABSTRACT Background The epidemiology of chronic hand eczema (CHE) remains poorly examined. Objective To investigate the prevalence CHE in a general adult population and describe characteristics affected individuals. Methods We investigated using random sample from Danish (The Skin Cohort). was defined as on hands or wrists during minimum three consecutive months reoccurrence at least twice within 12 months. Results Out 11 166 adults, 1306 experienced (HE) some point their lifetime. Within...

10.1111/cod.14732 article EN Contact Dermatitis 2025-01-05
Coming Soon ...